je.st
news
Tag: research collaboration
Reset Therapeutics, Inc. Establishes Research Collaboration With Alkermes For Discovery And Development Of Novel Orexin Modulators
2016-03-30 06:05:57| drugdiscoveryonline Home Page
Reset Therapeutics, Inc., announced recently a collaboration with an affiliate of Alkermes plc for the discovery, development and commercialization of novel orexin receptor modulators from Reset’s drug discovery platform
Tags: research
development
novel
collaboration
Lilly And AstraZeneca Expand Immuno-Oncology Research Collaboration With New Combinations
2015-10-26 04:26:54| drugdiscoveryonline News Articles
Eli Lilly and Company (NYSE: LLY) and AstraZeneca (NYSE:AZN) today announced an extension to their existing immuno-oncology collaboration exploring novel combination therapies for the treatment of patients with solid tumors.
Tags: research
expand
collaboration
combinations
Dow AgroSciences, Synthace Research Collaboration To Accelerate Product Development Using High Tech Tools
2015-10-05 03:59:44| chemicalonline Home Page
Synthace and Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company, recentlyannounce they have entered into a research collaboration to optimize technology by accelerating development of fermentation-based production of crop protection products. This Smart News Release features multimedia
Tags: high
product
tools
research
Viamet And Mycoses Study Group Education & Research Consortium Establish Collaboration To Advance A Novel Therapy For Cryptococcal Meningitis
2015-09-02 07:24:07| drugdiscoveryonline News Articles
Viamet Pharmaceuticals, Inc. and the Mycoses Study Group Education & Research Consortium (MSGERC) recently announced the establishment of a strategic collaboration to advance a novel therapy for cryptococcal meningitis and other life-threatening fungal infections
Tags: for
group
research
education
Merck and MD Anderson Cancer Center Announce Strategic Immuno-Oncology Research Collaboration in Solid Tumors
2015-08-13 14:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. & HOUSTON Clinical Trials to Evaluate Mercks KEYTRUDA (pembrolizumab) in Combination with Other Medicines and Treatments Across Multiple Tumor Types KENILWORTH, N.J. & HOUSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and The University of Texas MD Anderson Cancer Center today announced that they have entered into a strategic clinical research collaboration to evaluate Mercks anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in combination with other treatments, such as chemotherapy, radiation therapy and/or novel antitumor medicines. Language: English Contact: Merck Media Relations:Pamela Eisele, 267-305-3558orAn Phan, 908-255-6325orMerck Investor Relations:Justin Holko, 908-740-1879orMD Anderson Media Relations:Ron Gilmore, 713-745-1898Rlgilmore1@mdanderson.org Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: center
research
solid
cancer